Tag
Moderna and Merck's mRNA-4157 vaccine uses a cloud-based AI pipeline to create personalized cancer treatments, reducing recurrence risk by 49%. The FDA treats the AI software as part of the drug, marking a significant integration of technology in oncology.
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.